Author:
Jin C,Fan Y,Meng Y,Shen C,Wang Y,Hu S,Cui C,Xu T,Yu W,Jin J
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Urology,Oncology
Reference36 articles.
1. Paulson DF . Management of metastatic prostatic cancer. Urology 1985; 25 (2 Suppl): 49–52.
2. Harle LK, Maggio M, Shahani S, Braga-Basaria M, Basaria S . Endocrine complications of androgen-deprivation therapy in men with prostate cancer. Clin Adv Hematol Oncol 2006; 4: 687–696.
3. Magnan S, Zarychanski R, Pilote L, Bernier L, Shemilt M, Vigneault E et al. Intermittent vs continuous androgen deprivation therapy for prostate cancer: A systematic review and meta-analysis. JAMA Oncol 2015; 1: 1261–1269.
4. Boccon-Gibod L, Albers P, Morote J, van Poppel H, de la Rosette J, Villers A et al. Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer. Eur Urol 2014; 66: 655–663.
5. Nguyen PL, Je Y, Schutz FB, Hoffman KE, Hu JC, Parekh A et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: A meta-analysis of randomized trials. JAMA 2011; 306: 2359–2366.
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献